Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 4/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670474 | 1.00 | PARP1 (0.37) | PARP1KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL24469762 | 0.83 | PLAT (0.37) | KDM4EALDH1A1HPGDRAB9AHIF1A | |
| SCHEMBL24469869 | 0.81 | PDE3B (0.44) | KDM4EALDH1A1HPGDRAB9AHIF1A | |
| SCHEMBL24470000 | 0.68 | PDE3B (0.42) | PARP1KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL24469998 | 0.64 | PDE9A (0.43) | PARP1KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL24469822 | 0.63 | PLAT (0.32) | PLAT | |
| SCHEMBL4051794 | 0.62 | HPGD (0.58) | PARP1KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL22416468 | 0.62 | NOS3 (0.40) | KDM4EHPGDBTKCYP1A2 | |
| SCHEMBL4046309 | 0.61 | HPGD (0.54) | PARP1KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL17051317 | 0.61 | UHRF1 (0.39) | KDM4EHPGDAAK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | PARP1 2940/4885KDM4E 4358/4885ALDH1A1 648/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | PARP1 2940/4885KDM4E 4358/4885ALDH1A1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.